Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome

• Main Authors: John Jacob (Author), Vanessa Ribes (Author), Steven Moore (Author), Sean C. Constable (Author), Noriaki Sasai (Author), Sebastian S. Gerety (Author), Darren J. Martin (Author), Chris P. Sergeant (Author), David G. Wilkinson (Author), James Briscoe (Author)
• Format: Book
• Published: The Company of Biologists, 2014-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Fetal valproate syndrome (FVS) is caused by in utero exposure to the drug sodium valproate. Valproate is used worldwide for the treatment of epilepsy, as a mood stabiliser and for its pain-relieving properties. In addition to birth defects, FVS is associated with an increased risk of autism spectrum...